XOMA (LTS:0M26) Change In Receivables : $0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is XOMA Change In Receivables?

XOMA's change in receivables for the quarter that ended in Mar. 2024 was $1.00 Mil. It means XOMA's Accounts Receivable declined by $1.00 Mil from Dec. 2023 to Mar. 2024 .

XOMA's change in receivables for the fiscal year that ended in Dec. 2023 was $-1.00 Mil. It means XOMA's Accounts Receivable increased by $1.00 Mil from Dec. 2022 to Dec. 2023 .

XOMA's Accounts Receivable for the quarter that ended in Mar. 2024 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. XOMA's Days Sales Outstanding for the three months ended in Mar. 2024 was 0.18.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. XOMA's liquidation value for the three months ended in Mar. 2024 was $-0.44 Mil.

XOMA Change In Receivables Historical Data

The historical data trend for XOMA's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XOMA Change In Receivables Chart

XOMA Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-1.56

1.14

1.58

0.21

-1.00

XOMA Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															-0.01	-0.90	0.86	-0.96	1.00

XOMA Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

XOMA (LTS:0M26) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

XOMA's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.003	/	1.49	*	91
=	0.18

2. In Ben Graham's calculation of liquidation value, XOMA's accounts receivable are only considered to be worth 75% of book value:

XOMA's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	136.638	-	137.079	+	0.75 * 0.003	+	0.5 * 0
=	-0.44

XOMA Change In Receivables Related Terms

Thank you for viewing the detailed overview of XOMA's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

XOMA (LTS:0M26) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XOMA Corp (LTS:0M26) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

XOMAO.PFD:USA XOMAP.PFD:USA XOMA:USA X0M1:Germany

Address

2200 Powell Street, Suite 310, Emeryville, CA, USA, 94608

Website

https://www.xoma.com

XOMA Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.

XOMA (LTS:0M26) Headlines

No Headlines